Screener
Axsome Therapeutics AXSM Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's return on equity?
- Axsome Therapeutics (AXSM) reported return on equity of -349.4% in Q1 2026.
- How has Axsome Therapeutics's return on equity changed year-over-year?
- Axsome Therapeutics's return on equity decreased by 23.8% year-over-year, from -282.2% to -349.4%.
- What is the long-term trend for Axsome Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Axsome Therapeutics's return on equity has grown at a 29.1% compound annual growth rate (CAGR), from -70.4% to -252.1%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Axsome Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude